ECRIN is proud to announce that it has now published its 2018 annual report.

ECRIN participated in the EURORDIS Summer School from 10 to 14 June 2019 in Barcelona, Spain. 

​

ECRIN has now launched the 2019 call for its Data Centre Certification programme. 

This programme identifies non-commercial clinical trials units (CTUs) in Europe that have demonstrated they can provide safe, secure, compliant and efficient management of clinical research data.

EU-OPENSCREEN-DRIVE is offering funding for chemoproteomics and small molecule screen projects. 

5th Call for TRANSVAC2 Training Modules 

M10 - Assay Development and Validation-Application of SPR Technologies in Vaccine development and manufacturing

Venue: Fraunhofer IME, Aachen Germany
Dates: 10-11 October 2019

FAIR PARK II (Conservative Iron Chelation as a Disease-Modifying Strategy in Parkinson's Disease), an ECRIN-supported clinical trial, has released its June 2019 newsletter. 

The EULAC PerMed (Widening EU-CELAC policy and research cooperation in Personalised Medicine) project website is now online.

Health Research Board Clinical Research Coordination Ireland (HRB CRCI) hosted a conference to celebrate International Clinical Trials Day (ICTD) 2019.

The ECRAID-plan Consortium and Working Group meeting took place from May 20-21st in Amsterdam. The objectives of the consortium meeting were to:

Press Release – Paris, May 2019.

In April 2019 TRANSVAC2 launched a fourth call for Training Modules (M6,  M7 and M9) offered by the TRANSVAC2 project. The deadline has been extended to 1 June 2019. For more information, see below:

The PedCRIN funded WE Study (Walking Easier with cerebral palsy) is a double blind placebo controlled randomized trial in children between 4-17 years.

The Congress of join European Neonatal Societies (jENS 2019) represents a renowned interna

ECRIN 'CAMPUS' is back online!

ECRIN held a training session for auditors involved in its Data Management (DM) Centre Certification programme on 10 April 2019 in Paris. 

The PedCRIN-funded trial POPART (Prophylactic Oropharyngeal Surfactant for Preterm infant: A Randomised Trial) has started recruiting

The TRANSVAC2 project offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use. These services are not restricted to any disease in particular.